|By JCN Newswire||
|April 15, 2014 03:35 AM EDT||
The Honorary Knight Commander of the Order of the British Empire (KBE) award recognizes excellent achievement in a wide variety of fields and appreciates contributions to greater society, and is especially awarded to people who have left behind significant accomplishments, or people who have dedicated themselves to social services.
Statement from the British Embassy
Dr. Naito has continued to demonstrate steadfast commitment to the U.K. and Europe, acting as de facto figurehead for the British Government's campaign to attract investment from the Japanese life sciences industry. The most striking evidence of his championing of the U.K. is the GBP100 million investment in 2009
to build the European Knowledge Centre in Hatfield as Eisai's strategic base in Europe. Since then the company has further extended the British base to support its growing European, African and Middle Eastern business, and opened a new solid dose global manufacturing line for the anti-epileptic agent Fycompa in Hatfield in 2012. The company also continues to conduct ground-breaking research and
development in the U.K., including via its long-standing collaboration with University College London, with whom the company has an alliance to develop therapeutics for neurological disease.
Comment from Dr. Naito
It is a great honor to be appointed Honorary Knight Commander of the Order of the British Empire (KBE). Since Eisai established its first European office in London in 1988, we have built a strong relationship with the U.K. throughout the course of a quarter of a century. In 1990, Eisai established the Eisai London Research Laboratories at the University College London in the U.K., and has made many accomplishments through the exchange of knowledge and experience between leading scientists from the U.K. and Japan. In 2009, Eisai established the European Knowledge Centre, which integrates the company's European headquarters, research & development, production and marketing functions into one site, in Hatfield. Currently, it looks beyond Europe to the Middle East, Africa and Australia as well, and forms one of our primary global business units. Together with strengthening the positive mutual trust we have cultivated between Japan and the U.K. until now, we intend to take this honor as a further impetus to
realize the creation of innovative new medicines based on Britain's world-leading life science infrastructure, and make an even greater contribution to global health and welfare.
Eisai Co., Ltd. (TSE: 4523; ADR: ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.
Public Relations Department, Eisai Co., Ltd. +81-3-3817-5120
Copyright 2014 JCN Newswire. All rights reserved. www.japancorp.net
Jul. 7, 2015 08:15 PM EDT Reads: 1,104
Jul. 7, 2015 08:00 PM EDT Reads: 817
Jul. 7, 2015 07:00 PM EDT Reads: 2,649
Jul. 7, 2015 07:00 PM EDT Reads: 2,605
Jul. 7, 2015 06:30 PM EDT Reads: 1,006
Jul. 7, 2015 06:30 PM EDT Reads: 2,439
Jul. 7, 2015 05:45 PM EDT Reads: 2,499
Jul. 7, 2015 05:00 PM EDT Reads: 2,300
Jul. 7, 2015 05:00 PM EDT Reads: 2,491
Jul. 7, 2015 05:00 PM EDT Reads: 2,278
Jul. 7, 2015 04:45 PM EDT Reads: 1,735
Jul. 7, 2015 04:15 PM EDT Reads: 785
Jul. 7, 2015 04:00 PM EDT Reads: 1,974
Jul. 7, 2015 03:45 PM EDT Reads: 2,419
"In the IoT space we are helping customers, mostly enterprises and industry verticals where time-to-value is critical, and we help them with the ability to do faster insights and actions using our platform so they can transform their business operations," explained Venkat Eswara, VP of Marketing at Vitria, in this SYS-CON.tv interview at @ThingsExpo, held June 9-11, 2015, at the Javits Center in New York City.
Jul. 7, 2015 03:45 PM EDT Reads: 982